Physician profile
Patrick K Chin
NPI 1396702783
$9,443.26
in general payments reported to CMS, 2019-2025
26 companies · $966 in 2025
The $966 reported for 2025 was more than what 76% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,628 · 2020: $402 · 2021: $450 · 2022: $739 · 2023: $227 · 2024: $5,031 · 2025: $966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $4,128 · Food and Beverage: $2,097.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $4,127.83 |
| Food and Beverage | $2,096.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $5,255.88 | 2020-2025 | Idose, Istent, Idosetr |
| Johnson & Johnson Surgical Vision, INC. | $1,314.99 | 2019-2025 | Tecnis Iol, Tecnis Iol, Catalys System |
| Rxsight INC | $444.63 | 2024-2025 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Allergan, INC. | $403.75 | 2019-2022 | |
| Abbvie INC. | $309.93 | 2022-2025 | Alphagan P, Lumigan, Durysta |
| Bausch & Lomb Americas INC. | $274.04 | 2022-2025 | Envista Mx60 Iol, Miebo, Xiidra |
| Alcon Vision LLC | $208.03 | 2019-2025 | Clareon, Rocklatan, Clareon Panoptix Pro |
| Sun Pharmaceutical Industries INC. | $166.19 | 2019-2023 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $144.12 | 2019-2021 | |
| Oyster Point Pharma, INC. | $128.40 | 2022-2025 | Tyrvaya |
| Sight Sciences, INC. | $125.60 | 2021-2025 | Omni Surgical System |
| Novartis Pharmaceuticals Corporation | $117.46 | 2020-2023 | |
| Kala Pharmaceuticals, INC. | $98.55 | 2020-2021 | |
| Aerie Pharmaceuticals, INC. | $86.46 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $72.15 | 2021-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $57.00 | 2024 | Xdemvy |
| Shire North American Group INC | $39.92 | 2019 | |
| Mallinckrodt Hospital Products INC. | $32.29 | 2023 | Acthar |
| Ocular Therapeutix, INC. | $30.63 | 2021-2022 | |
| Horizon Therapeutics Plc | $26.38 | 2023 | Tepezza |
| New World Medical,INC. | $21.78 | 2025 | Kahook Dual Blade, Ahmed Glaucoma Valve, Clearpath |
| Eyevance Pharmaceuticals LLC | $21.71 | 2021 | |
| Dompe US, INC. | $18.68 | 2025 | Oxervate |
| Coopervision INC. | $18.48 | 2023 | Misight Contact Lens |
| Harrow Eye, LLC | $13.38 | 2023 | Vevye |
| Alexion Pharmaceuticals, INC. | $12.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Chin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.